drugset / Trial / NCT06438783
TQB2928 Injection Combined Anlotinib Hydrochloride Capsule in Recurrent/Metastatic Osteosarcoma and Other Solid Tumors
Phase 1
Terminated
20 enrolled
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, multi-cohort Phase Ib trial to evaluate the efficacy and safety of TQB2928 injection combined with anlotinib hydrochloride capsule in patients with relapsed/metastatic osteosarcoma and other relapsed/metastatic solid tumors.
Timeline
- Start
- 2024-02-15
- Primary completion
- 2025-06-18
- Completion
- 2025-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | — | — |
| Subject | TQB2928 | Monoclonal antibody | 1200 mg | — |
| Subject | TQB2928 | Monoclonal antibody | 1800 mg | — |